Luis Javier
Luis Javier Artieda, Sr., Lauderhill, FL US
Patent application number | Description | Published |
---|---|---|
20110043161 | Electric wheels - Our invention is focus on the fields of ecology and terrestrial transportation. The goal is to reduce the use of no-renewable fuels, as well as to reduce pollution consequences (the ecological impact). | 02-24-2011 |
Luis Javier Cruz Ricondo, C. Habana CU
Patent application number | Description | Published |
---|---|---|
20090104223 | Method for Obtaining Antigenic Aggregates and the Use Thereof in Formulations - The invention relates to a method for obtaining aggregated antigenic structures that are capable of enhancing an immune response to aggregate antigens administered systemically and/or mucosally generating powerful immune response and to the chemical structures resulting from the application of said method, to the formulations obtained from such structures and their use. The method describes the obtention of novel aggregate antigenic structures by using aggregating, delipidating or oxidating agents or compounds enabling the release of lipids from the particles and their heterogeneous aggregation, wherein aggregates with particle sizes of between 30 and 500 nm are subsequently selected by means of a molecular exclusion process. The aggregation state can also be provoket inside the yeast by changing incubation conditions. The resulting structures can be used conveniently adjuvated or in a formulation in which several antigens can be introduced, wherein synergism between said components is found with respect to the immunogenicity of the response obtained. The preparation may also contain stabilizers and preservatives. The resulting antigenic structures can be used in the pharmaceutical industry as preventive or therapeutic vaccine formulation both for human and veterinary use and as part of diagnostic system. | 04-23-2009 |
Luis Javier Cruz Ricondo, Leiden NL
Patent application number | Description | Published |
---|---|---|
20150374734 | ACTIVATION OF iNKT CELLS - The present invention relates to particulate entity, such as a nanoparticle or conjugate, for use in particular as adjuvant in vaccine or immunotherapy. More specifically, the invention relates to a particulate entity comprising: iv. an iNKT cell agonist such as α Gal Car compound, and, v. one or more antigenic determinant(s) such as a tumour antigen(s) or pathogen-derived antigen(s), vi. a targeting agent that targets in vivo said iNKT cell agonist to dendritic cells, such as human BDCA3+ dendritic cells. | 12-31-2015 |
Luis Javier Cruz Ricondo, Nijmegen NL
Patent application number | Description | Published |
---|---|---|
20150250905 | CONTRAST AGENT AND ITS USE FOR IMAGING - The present invention relates to contrast agent enhanced medical ultrasound imaging. In particular, the contrast agents provided are useful for cell imaging and cell therapy, as well as in vivo targeting, drug delivery and perfusion or vascular imaging applications. More specifically, it provides a particle comprising a fluorinated organic compound and a metal. Such particles may be advantageously employed in qualitative or quantitative imaging such as acoustic imaging including photoacoustic and ultra-sound imaging, MRI imaging, such as 19F imaging, 1H imaging including T1 and T2 weighted imaging, SPECT, PET, scintigraphy, fluorescence imaging and optical coherence imaging and tomographic applications. This may then be employed in cell labeling, microscopy, histology or for imaging vasculature or perfusion in vivo and in vitro. | 09-10-2015 |
Luis Javier Gonzalez Lopez, Ciudad De La Habana CU
Patent application number | Description | Published |
---|---|---|
20090005294 | Peptides for the Treatment of Cancer Associated with the Human Papilloma Virus (HPV) and Other Epithelial Tumors - This invention is related to the Molecular Pharmacology field and especially to the development of peptides useful for treating epithelial tumors and mainly those associated to oncogenic types of HPVs. The main objective of this invention is to identify peptides whose structure permits to block the Casein Kinase II (CKII) phosphorylation domain by direct interaction with such a site. In the present invention it is shown eleven cyclic peptides with different aminoacid sequences which inhibit the CKII phosphorylation in vitro, exhibit cytotoxicity on HPV-16 transformed cells (CaSki) and also increase the sensitivity of these cells to the cytostatic effect of interferon (IFN). Furthermore, the invention relates to the use of these peptides conjugated or fused to other peptides and chemical compounds which penetrates into cells as well as with the use of both peptide and chemical mimetic molecules. | 01-01-2009 |
20090130228 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT AND OR CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS - This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomicin C, imatinib, iressa and velcade (vortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics. | 05-21-2009 |
20150030700 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT AND/OR CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS - This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa and velcade (bortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics. | 01-29-2015 |
20150111832 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT AND/OR CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS - This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa, velcade (bortezomib), cytarabine (Ara C), fludarabine and mitroxantrone. The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics. | 04-23-2015 |
Luis Javier González López, Ciudad De La Habana CU
Patent application number | Description | Published |
---|---|---|
20110212105 | METHOD TO BLOCK THE INFECTION BY FLAVIVIRUSES, MOLECULES AND USES - The present invention is related to a method for blocking the infection of cells by dengue virus, based on interfering the direct interaction of the viral envelope protein with a cellular receptor or its indirect interaction with said cellular receptor through a carrier protein, as well as related uses; wherein said cellular receptor is the alpha-2 macroglobulin receptor, also known as the low density receptor-related protein or as CD91, and said carrier protein is human alpha-2 macroglobulin. | 09-01-2011 |
20110218138 | Pharmaceutical composition containing polypeptide fragments of serralysins - The present invention is related to a composition capable of inhibiting the growth of tumoral cells of different histological origins and of activated endothelial cells. The components of said compositions are polypeptide fragments of the serralisins, corresponding to the C-terminal fragment, from the internal metionine trough the end of the molecule, which could be combined among them and optionally with the prodigiosins that potentiate the antitumoral effect of the composition. The prodigiosins in the composition could be at a concentration of 0.1-100 nM. The anti-proliferative action of this composition is mediated by apoptotic mechanism. It's “in vivo” administration has antitumoral, antiangiogenic and protective effect against malignant tumors. | 09-08-2011 |
Luis Javier González López, La Habana CU
Patent application number | Description | Published |
---|---|---|
20140356319 | Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases - The present invention describes peptides comprising phycocyanobilin (PCB), as well as the medical use of said peptides and that of PCB, due to the neuroprotector and/or neuroregenerative effects identified for them. Furthermore, pharmaceutical combinations of said peptides and of PCB with proteins or other peptides with synergic effect justify their use for ischemic or neurodegenerative CNS disease treatment. | 12-04-2014 |
Luis Javier Hoyos Marin, Santander CO
Patent application number | Description | Published |
---|---|---|
20110143932 | METHOD FOR PRODUCING VANADIUM TRAPS BY MEANS OF IMPREGNATION AND RESULTING VANADIUM TRAP - The invention relates to a method for preparing a chemical composition obtained by co-impregnating water-soluble salts Ba/Mg and phosphoric acid H | 06-16-2011 |
20110152071 | VANDIUM TRAPS FOR CATALYTIC CRACKING PROCESSES AND PREPARATION THEREOF - The invention relates to chemical compositions that can be used for hydrocarbon catalytic cracking processes with vanadium as a contaminant, including an active phase formed by different pyrophosphates M2P2O7 (M=Ba or Ca) supported on a mixture of magnesium and aluminium oxide, preferably magnesium aluminate in the spinel phase. The composition captures the metals originating from the charge, particularly vanadium, and thus protects the catalyst. Said composition is preferably used in the form of a separated particle in order to the control the addition thereof to the unit according to the metal content of the charge. The invention also relates to the method for preparing said composition, including synthesis of pyrophosphates, formation of a suspension of boehmite alumina, magnesium oxide or magnesium hydroxide, together with oxides M2P2O7, spray drying and calcination of the microspheres without generating any loss in the crystalline structure of oxides M2P2O7. | 06-23-2011 |
Luis Javier Juarez Vargas, Delegacion: Gustavo A. Madero MX
Patent application number | Description | Published |
---|---|---|
20080262017 | Sugar-Free Storage-Stable Antihistaminic Syrups - New and improved storage-stable sugar-free antihistaminic syrups are disclosed. | 10-23-2008 |
Luis Javier Puras Trueba US
Patent application number | Description | Published |
---|---|---|
20110195617 | Contact Arrangement For Connection With A Polygonal Socket - The invention relates to an electrical contact arrangement for high pulsed currents and for connection with a polygonal socket. The electrical contact arrangement includes first contact, arm, a second contact arm, an intermediate space provided between the first and second contact arms, and a third contact arm. The second contact arm positioned apart from the first contact arm in a deflection direction extending perpendicularly to the plug-in direction. The first contact arm and second contact arm extend substantially in a plug-in direction, and one of the first contact arm or second contact arm resiliently deflectable relative to the other contact arm in the deflection direction. The third contact arm extends in the plug-in direction and is positioned apart from the first contact arm and the second contact arm in a transverse direction extending perpendicularly to the plug-in and deflection directions. The third contact arm movable in the deflection direction and into the intermediate space. | 08-11-2011 |
Luis Javier Rogla Madrid, Tres Cantos ES
Patent application number | Description | Published |
---|---|---|
20150025862 | METHOD FOR EQUALIZING THE DISTORTION CAUSED BY LOSSES IN COUPLINGS IN A MICROWAVE FILTER AND A FILTER PRODUCED WITH SAID METHOD - A method for equalizing the distortion caused by losses in couplings in a microwave filter comprising the steps of: designing an initial transfer function of a filter; calculating the poles p | 01-22-2015 |